Company intelligence / Profile preview

Tridem Bioscience

Vienna, Vienna, Austriatridem.at ↗

Ownership: Private
Development stage: Other

Overview

Tridem Bioscience has demonstrated preclinical proof-of-concept for its proprietary WISIT vaccine platform targeting human alpha-synuclein in Parkinson’s disease, showing superior immune responses compared to conventional vaccines in vitro and in vivo models. No clinical trial results are available yet.

Therapeutic areas: Neurology
Modalities: Vaccineβ-glucan-based neoglucoconjugate vaccinePeptides (peptide-based vaccines)Protein (carrier protein conjugates)
Industry: Biotech

Drug pipeline

3 assets

TRB-001

2 more assets in the full pipeline.

Partnerships

NEXGEN-PD consortium, including Paracelsus Medical University and partners from Austria, Hungary, France, Germany, and the Netherlands for research on early diagnosis and treatment of Parkinson’s Disease using their platform.

Beyond the preview

Go deeper on Tridem Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tridem Bioscience.